Reolysin Combo Given to 1st Patient in Phase 1 Trial for Relapsing Myeloma
The Phase 1b clinical trial called MUK eleven (NCT03015922) testing Reolysin (pelareorep) as a combination therapy for relapsing myeloma patients has dosed its first…
News
Safety Concerns Lead to Partial Hold of 2 Tecentriq Trials in Myeloma, Lymphoma
Based on recently published safety data, two clinical trials evaluating combinations of Tecentriq (atezolizumab) in multiple myeloma and follicular lymphoma patients were placed on partial clinical hold at…
Sellas’ Cancer Vaccine Galinpepimut-S Shows Durable Effects in High-risk Myeloma Patients
Sellas Life Sciences’ cancer vaccine galinpepimut-S showed promising effects in patients with an aggressive form of multiple myeloma, researchers said in a presentation at…
Unum’s T-Cell Therapy Enters Phase 1 Trial for Relapsed or Refractory Multiple Myeloma
The U.S. Food and Drug Administration (FDA) recently approved an investigational new drug (IND) application filed by Unum Therapeutics for its ACTR087 T-cell therapy…
Poseida’s Myeloma-specific CAR T-cells Combat Aggressive Cancer in Mice, Study Shows
Poseida Therapeutics demonstrated that their new CAR T-cell treatment for multiple myeloma — P-BCMA-101 — possessed features that make it stand out in the…
Myeloma Tests Could Confuse Doctors into Suspecting Relapse, Study Argues
Lab tests used to evaluate treatment response after a stem cell transplant for multiple myeloma could lead physicians to wrongfully believe that a patient is…
Safety Concerns About Other Therapies Prompt FDA to Put a Hold on Three Opdivo Combo Trials
The U.S. Food and Drug Administration has ordered Bristol-Myers Squibb to put a hold on three clinical trials evaluating Opdivo (nivolumab) in combination with…
FDA Halts Imfinzi Combination Trials After Unexplained Keytruda-related Deaths
The U.S. Food and Drug Administration (FDA) suspended a Phase 1 clinical trial testing a combination of AstraZeneca‘s Imfinzi (durvalumab) with an immunomodulatory and an anti-cancer…
Long-term Data Confirms Kyprolis Survival Benefit in Relapsed Myeloma Patients
New long-term data from the Phase 3 ENDEAVOR trial has shown that relapsed multiple myeloma patients treated with Kyprolis (carfilzomib) plus dexamethasone survive a median of…
Kyprolis Combo Treatment Extends Survival of Relapsed Myeloma Patients, ENDEAVOR Study Shows
Relapsed multiple myeloma patients who receive Kyprolis (carfilzomib) plus dexamethasone as their second-to-fourth treatment regimen survive a median of 7.6 months longer than those…
Recent Posts
- Germany clears pelareorep pancreatic cancer trial continuation
- FDA grants orphan drug status to novel brain cancer treatment
- Medicaid expansion can raise demand for gynecologic cancer care
- Under-the-skin Sarclisa found as effective as approved formulation
- FDA gives LYT-200 fast track status as potential AML treatment